497 related articles for article (PubMed ID: 26320060)
1. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
Obeid J; Hu Y; Slingluff CL
Semin Oncol; 2015 Aug; 42(4):549-61. PubMed ID: 26320060
[TBL] [Abstract][Full Text] [Related]
2. Cancer vaccines.
Butterfield LH
BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
[TBL] [Abstract][Full Text] [Related]
3. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
4. Priming anticancer active specific immunotherapy with dendritic cells.
Mocellin S
Curr Opin Investig Drugs; 2005 Jun; 6(6):576-81. PubMed ID: 15988908
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines: a critical review on clinical impact.
Bitton RJ
Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
[TBL] [Abstract][Full Text] [Related]
6. Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.
Fernández A; Oliver L; Alvarez R; Fernández LE; Lee KP; Mesa C
Hum Vaccin Immunother; 2014; 10(11):3251-60. PubMed ID: 25483674
[TBL] [Abstract][Full Text] [Related]
7. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
8. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
[TBL] [Abstract][Full Text] [Related]
9. Review: cancer immunotherapy by exosome-based vaccines.
Hao S; Moyana T; Xiang J
Cancer Biother Radiopharm; 2007 Oct; 22(5):692-703. PubMed ID: 17979572
[TBL] [Abstract][Full Text] [Related]
10. A review of dendritic cell therapy for cancer: progress and challenges.
Mantia-Smaldone GM; Chu CS
BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines: an update.
Hipp JD; Hipp JA; Lyday BW; Minev BR
In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
[TBL] [Abstract][Full Text] [Related]
12. How much help does a vaccine-induced T-cell response need?
Weber JS; Mulé JJ
J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
[No Abstract] [Full Text] [Related]
13. Advances in Therapeutic Cancer Vaccines.
Wong KK; Li WA; Mooney DJ; Dranoff G
Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based vaccine research against cancer.
Mody N; Dubey S; Sharma R; Agrawal U; Vyas SP
Expert Rev Clin Immunol; 2015 Feb; 11(2):213-32. PubMed ID: 25467734
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells in cancer vaccines.
Brossart P; Wirths S; Brugger W; Kanz L
Exp Hematol; 2001 Nov; 29(11):1247-55. PubMed ID: 11698120
[TBL] [Abstract][Full Text] [Related]
16. New trends in the development of cancer vaccines.
Minev BR; Chavez FL; Mitchell MS
In Vivo; 1998; 12(6):629-38. PubMed ID: 9891226
[TBL] [Abstract][Full Text] [Related]
17. [Active immunotherapy of prostate cancer with a focus on dendritic cells].
Thomas-Kaskel AK; Veelken H
Actas Urol Esp; 2007 Jun; 31(6):668-79. PubMed ID: 17896564
[TBL] [Abstract][Full Text] [Related]
18. Vaccines: an innovative approach to treating cancer.
Pazdur MP; Jones JL
J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
[TBL] [Abstract][Full Text] [Related]
19. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
20. Cancer vaccines entering Phase III clinical trials.
Durrant LG; Spendlove I
Expert Opin Emerg Drugs; 2003 Nov; 8(2):489-500. PubMed ID: 14662001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
